Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer

Biomarkers

Volumn 12, Issue 6, 2007, Pages 657-667

  Baskić, Dejan ^a   Ristić, Petar ^a   Matić, Snežana ^a   Banković, Dragić ^a   Popović, Suzana ^a   Arsenijević, Nebojša ^a  

^a UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Breast cancer; CA 125; CA 15 3; Serum levels; sHER2

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER LOCALIZATION; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS;

BREAST NEOPLASMS; CA-125 ANTIGEN; CA-15-3 ANTIGEN; CASE-CONTROL STUDIES; FEMALE; HUMANS; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 35748976558     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500701520563     Document Type: Article

References (44)

1. Anonymous (1996) Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer by the American Society of Clinical Oncology. Journal of Clinical Oncology, 14, pp. 2843-2877.
2. Berruti, A., Tampellini, M., Torta, M., Buniva, T., Gorzegno, G. and Dogliotti, L. (1994) Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. European Journal of Cancer, 30, pp. 2082-2084.
3. Bon, GS, von Mensdorff-Poully, S., Kenemans, P., van Kamp, GJ, Verstraeten, RA and Hilgers, J. (1997) Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assay. Clinical Chemistry, 43, pp. 585-593.
4. Buamah, P. (2000) Benign conditions associated with raised serum CA 125 concentration. Journal of Surgical Oncology, 75, pp. 264-265.
5. Canizares, F., Sola, J., Perez, M., Tovar, I., Heras, M De Las and Salinas, J. (2001) Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: A multivariate analysis. Tumor Biology, 22, pp. 273-281.
6. Carney, WP, Neumann, R., Lipton, A., Leitzel, K., Ali, S. and Price, CP (2003) Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clinical Chemistry, 49, pp. 1579-1598.
7. Codony-Servat, J., Albanell, J., Lopez-Talavera, JC, Arribas, J. and Baselga, J. (1999) Cleavage of the HER-2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Research, 59, pp. 1196-1201.
8. Colomer, R., Montero, S., Lluch, A., Ojeda, B., Barnadas, A. and Casado, A. (2000) Circulating HER-2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clinical Cancer Research, 6, pp. 2356-2362.
9. Doroudchi, M., Talei, A., Modjtahedi, H., Dehaghani, AS, Pezeshki, AM and Thomas, H. (2005) Serum level of HER-2 extracellular domain in Iranian patients with breast cancer: A follow-up study. Iranian Journal of Immunology, 2, pp. 191-199.
10. Duffy, MJ, Shering, SG, Sherry, F., McDermott, E. and O'Higgins, N. (1996) Proceedings of the XVI International Congress of Clinical Chemists, Association of Clinical Biochemists, London
11. Duffy, MJ (1999) CA 15-3 and related mucins as circulating markers in breast cancer. Annals of Clinical Biochemistry, 36, pp. 579-586.
12. Eskelinen, M., Kataja, V., Hamalainen, E., Kosma, VM, Penttila, I. and Alhava, E. (1997) Serum tumor markers CEA, AFP, CA15-3, TPS and neu in diagnosis of breast cancer. Anticancer Research, 17, pp. 231-234.
13. Gendler, SJ and Spicer, AP (1995) Epithelial mucin genes. Annual Review of Physiology, 57, pp. 607-634.
14. Geraghty, J., Coveney, EC, Sherry, F., O'Higgins, NJ and Duffy, MJ (1992) CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer, 70, pp. 2831-2834.
15. Hardardottir, H., Parmley, TH 2nd, Quirk Jr, JG, Sanders, MM, Miller, FC and O'Brien, TJ (1990) Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. American Journal of Obstetrics & Gynecology, 163, pp. 1925-1931.
16. Harris, LN, Liotcheva, V., Broadwater, G., Ramirez, MJ, Maimonis, P. and Anderson, S. (2001) Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. Journal of Clinical Oncology, 19, pp. 1698-1706.
17. Hayes, DF, Zurawski, VR and Kufe, D. (1986) Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. Journal of Clinical Oncology, 4, pp. 1542-1550.
18. Henry, NL and Hayes, DF (2006) Uses and abuses of tumor markers in the diagnosis, monitoring and treatment of primary and metastatic breast carcinoma. Oncologist, 11, pp. 541-552.
19. Jensen, BV, Johansen, JS and Price, PA (2003) High levels of serum HER-2/ neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clinical Cancer Research, 9, pp. 4423-4434.
20. Kong, S-Y, Kang, JH, Kwon, Y., Kang, H-S, Chung, K-W and Kang, SH (2006) Serum HER-2 concentration in patients with primary breast cancer. Journal of Clinical Pathology, 59, pp. 373-376.
21. Leonard, GD, Low, JA, Berman, AW and Swain, SM (2004) CA 125 elevation in breast cancer: A case report and review of the literature. The Breast Journal, 10, pp. 146-149.
22. Lipton, A., Leitzel, K., Ali, SM, Demers, L., Harvey, HA and Chaudri-Ross, HA (2005) Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer, 104, pp. 257-263.
23. Maguire, HC and Greene, MI (1989) The neu (c-erbB-2) oncogene. Seminars in Oncology, 16, pp. 148-155.
24. Meyer, T. and Rustin, GJS (2000) Role of tumour markers in monitoring epithelial ovarian cancer. British Journal of Cancer, 82, pp. 1535-1538.
25. Molina, R., Filella, X., Zanon, G., Pahisa, J. and Munoz, M. (1996) C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Research, 16, pp. 2295-2300.
26. Molina, R., Zanon, G., Filella, X., Farrus, B. and Munoz, M. (1996) Utility of c-erbB-2 in tissue and serum in the early diagnosis of recurrence in breast cancer patients: Comparison with carcinoembryonic antigen and CA 15-3. British Journal of Cancer, 74, pp. 1126-1131.
27. Nichols, HB, Trentham-Dietz, A., Love, RR, Hampton, JM, Anh, P Thi Hoang and Allred, DC (2005) Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiology. Biomarkers & Prevention, 14, pp. 41-47.
28. Norum, LF, Erikstein, B. and Nustad, K. (2001) Elevated CA 125 in breast cancer - a sign of advanced disease. Tumor Biology, 22, pp. 223-228.
29. Omar, YT, Behbehani, AE, al-Naqeeb, N., Motawy, MM, Foudeh, MO and Awwad, AH (1989) Preoperative and longitudinal serum levels of CA 125 and CA 15.3 in patients with breast cancer. International Journal of Biological Markers, 4, pp. 81-86.
30. Pichon, MF, Hacene, K., Guepratte, S. and Neumann, R. (2004) Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients. Clinical Laboratory, 50, pp. 163-170.
31. Pilo, A., Zucchelli, GC, Cohen, R., Bizollon, C., Capelli, G. and Cianetti, A. (1995) Comparison of immunoassay for tumor markers CA 19-9, CA 15-3 and CA 125: Data from an international quality assessment scheme. Tumori, 81, pp. 117-124.
32. Pupa, SM, Menard, S., Morelli, D., Pozzi, B., De Palo, G. and Colnaghi, MI (1993) The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene, 8, pp. 2917-2923.
33. Safi, F., Kohler, I., Rottinger, E. and Beger, HG (1991) The value of tumor marker CA 15-3 in diagnosis and monitoring breast cancer. Cancer, 68, pp. 574-582.
34. Schippinger, W., Regitnig, P., Bauernhofer, T., Ploner, F., Hofmann, G. and Krippl, P. (2004) The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Oncology Reports, 11, pp. 1331-1336.
35. Schwartz, MK, Smith, C., Schwartz, DC, Dnistrian, A. and Neiman, I. (2000) Monitoring therapy by serum HER-2/neu. International Journal of Biological Markers, 15, pp. 324-329.
36. Shering, S., Sherry, F., McDermott, E., O'Higgins, N. and Duffy, MJ (1998) Preoperative CA 15-3 concentrations predict outcome in breast cancer. Cancer, 83, pp. 2521-2527.
37. Slamon, DJ, Godolphin, W., Jones, LA, Holt, JA, Wong, SG and Keith, DE (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, pp. 707-712.
38. Sobin, LH and Wittekind, CH (1997) TNM Classification of Malignant Tumours, Wiley-Liss, New York, NY
39. Sommer, SS, Cunningham, J., McGovern, RM, Saitoh, S., Schroeder, JJ and Wold, LE (1992) Pattern of p53 gene mutations in breast cancers in women of the Midwestern United States. Journal of National Cancer Investigations, 84, pp. 246-252.
40. Sugano, K., Ushiama, M., Fukutomi, T., Tsuda, H., Kitoh, T. and Ohkura, H. (2000) Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. International Journal of Cancer, 89, pp. 329-336.
41. Tampellini, M., Berruty, A., Bitossi, R., Gorzegno, G., Alabiso, I. and Bottini, A. (2006) Prognostic significance of changes in CA 15-3 serum level during chemotherapy in metastatic breast cancer patients. Breast Cancer Research and Treatment, 98, pp. 241-248.
42. Watanabe, N., Miyamoto, M., Tokuda, Y., Kubota, M., Ando, Y. and Tajima, T. (1994) Serum c-erbB-2 in breast cancer patients. Acta Oncologica, 33, pp. 901-904.
43. Weiss, SE, Tartter, P., Ahmed, S., Brower, S., Brusco, C. and Bossolt, K. (1995) Ethnic differences in risk and prognostic factors for breast cancer. Cancer, 76, pp. 268-274.
44. Wesseling, J., van der Valk, SW and Hilkens, J. (1996) A mechanism for inhibition of E-cadherin-mediated cell/cell adhesion by the membrane-associated mucin episialin/MUC1. Molecular Biology of the Cell, 7, pp. 565-577.